Skip to content
TrialScanner

NCT04278144

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Phase 1/Phase 2TerminatedBOLTLeadBMYCollaborator

Registry record

Lead sponsor
Bolt Biotherapeutics, Inc.
Conditions
HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Colorectal Cancer; HER2-positive Gastroesophageal Cancer; HER2-positive Endometrial Cancer
Primary completion
Dec 10, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04278144 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04278144: A First-in-human Study Using... | TrialScanner